Powered replication studies in homogeneous cohorts of ovarian cancer patients treated with standard cisplatin-based chemotherapy will enable a better understanding of the prognostic and predictive relevance of HOXD8 gene expression as a potential biomarker of cisplatin-resistance and metastasis. This evidence concerns the gene HOXD8 and ovarian carcinoma.